Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2019
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - January 20, 2019

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/21/18 - BITTER PILLS TO SWALLOW - NO RESTRICTIONS ON ONLINE SALES OF MEDICINES FOR NOW: MADRAS HIGH COURT
The Madras High Court has stated that there is no restriction on online sales of medicines for now until it delivers the final order. It had banned online sales of drugs from 20 Dec 2018 until the Government of India notified regulations for the industry. The annual turnover of the online pharmacy industry is Rs1, 500-1,800 crore, says the Indian I
12/21/18 - CathWorks FFRangio? System Receives U.S. FDA Clearance
Enables non-invasive, objective functional evaluation of multi-vessel coronary artery disease. KFAR-SABA, Israel& ALISO VIEJO, Calif. CathWorks announced today that its FFRangio? System received United States Food& Drug Administration 510 clearance. Jim Corbett, CathWorks CEO said, The FDA clearance of CathWorks FFRangio is a significant m
12/21/18 - Chinese Citizens Sentenced in Scheme to Sell Mislabeled Dietary Supplements
Zhang Xiao Dong, of Shanghai, China, was sentenced in Dallas today to 24 months' imprisonment and two years of supervised release in connection with a scheme to sell mislabeled dietary supplements, the Department of Justice announced. Zhang pleaded guilty in April 2018 in the Northern District of Texas to one count of mail fraud. Gao also admitted
12/21/18 - PLx Pharma Inc. Announces $15 Million Convertible Preferred Stock Financing
PLx Pharma Inc., a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore? 325 mg and Vazalore? 81 mg, announced today it has signed a stock purchase agreement with funds affiliated with Park West Asset Management LLC to purchase 15,000 shares of newly issued Series A Convertible Preferr
12/20/18 - "Multi Chamber Flexible Bag And Methods Of Using The Same" in Patent Application Approval Process (USPTO 20180344569)
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventor DI NARO, Antonio Francesco, filed on May 31, 2017, was made available online on December 6, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to ADIENNE Pharma& Biotech SA.
12/20/18 - "pharmaceutical Composition for Inhibition of Cancer Cell Metastasis Including siRNA for Ribosomal Protein S3" in Patent Application Approval Process (uspto 20180346915)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week A patent application by the inventors KIM, Joon; KIM, Hag Dong; KIM, YongJoong, filed on June 21, 2017, was made available online on December 6, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assign
12/20/18 - "Pharmaceutical Composition For Injection" in Patent Application Approval Process (USPTO 20180344831)
By a News Reporter-Staff News Editor at Cancer Vaccine Week A patent application by the inventors TANAKA, Satoshi; NAKATANI, Tomomi, filed on September 26, 2015, was made available online on December 6, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Sumitomo Da
12/20/18 - 'DRUG$'Documentary Now Streaming on YouTube and Amazon Prime
DRUG$, a new documentary that explores the mystery of modern medicine s skyrocketing price tag here in the U.S. and how it affects people struggling to stay alive, is now widely available to the public streaming on Amazon Prime and YouTube after finishing a weeklong theatrical run in Los Angeles at the Laemmle Music Hall 3 in Beverly Hills. Canc
12/20/18 - [I-bank focus]UBS lowers Sino Biopharma (01177) to HK$6.67 [ET Net News (China)]
UBS lowered its target price for Sino Biopharma. to HK $6.67 from HK $13 and maintained its "buy" rating. The research house said they update their forecast after the recent big price cut on 31.
12/20/18 - 2018 Global Legionella Diagnostics Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, and Opportunities for Suppliers - ResearchAndMarkets.com
The "2018 Global Legionella Diagnostics Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers" report has been added to ResearchAndMarkets.com' s offering. The report presents a detailed analysis of the Legionella diagnostics market in the US, Europe and Japan.
12/20/18 - 2018 Global Pseudomonas Diagnostics Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, and Opportunities for Suppliers - ResearchAndMarkets.com
The "2018 Global Pseudomonas Diagnostics Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers" report has been added to ResearchAndMarkets.com' s offering. The report presents a detailed analysis of the Pseudomonas diagnostics market in the US, Europe and Japan.
12/20/18 - 2018 Global Rabies Diagnostics Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers - Forecast to 2023 - ResearchAndMarkets.com
The "2018 Global Rabies Diagnostics Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers" report has been added to ResearchAndMarkets.com' s offering. The report presents a detailed analysis of the Rabies diagnostics market in the US, Europe and Japan.
12/20/18 - 5 Top Biotech and Pharma Stocks on the TSX Year-to-Date
As we move into 2019, the Investing News Network is profiling the top five biotech stocks on the Toronto Stock Exchange year-to-date. The companies listed below have market caps between C $50 million and C $500 million. Landing first on our top pharma and biotech stocks TSX year-to-date list is Bellus Health.
12/20/18 - 50S Ribosomal Subunit (50S RNA) Inhibitor Pipeline Insight, 2018 Report
The "50 S Ribosomal Subunit Inhibitor- Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com' s offering. 50 S Ribosomal Subunit Inhibitor- Pipeline Insight, 2018' report offers comprehensive insights of the pipeline therapeutics scenario and growth prospects across 50 S Ribosomal Subunit Inhibitor development.
12/20/18 - 7 Stocks That Made Big Moves After-hours (TLRY, SPPI, ADMA, DBVT...)
A day after signing a deal with Sandoz AG, a division of Novartis, Canadian Cannabis Company Tilray Inc. has entered into a partnership with AB InBev, the world's leading brewer. The partnership with AB InBev, which is limited to Canada, will focus on non-alcohol beverages containing tetrahydrocannabinol and cannabidiol, combining AB InBev's deep e
12/20/18 - A Multi-Center Cluster Randomized Controlled Clinical Trial to Determine the Impact of a Mobile Health Application on Rheumatoid Arthritis Shared Decision Making
By a News Reporter-Staff News Editor at Health& Medicine Week Staff editors report on the newly launched clinical trial, NCT03773471, which has the following summary description: "Our overall goal is to improve shared decision-making about treatment options and thereby enhance disease outcomes and health-related quality of life for patients with.
12/20/18 - A Multicenter Clinical Study to Optimize the Therapeutic Pathway of Peginterferon Alfa-2b Treatment in Patients With Chronic Hepatitis B Based on IFNA2p.Ala120Thr /ISGs Gene Spectrum
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03771677, which has the following summary description: "The study is to optimize the clinical therapeutic pathway of peginterferon alfa-2a treatment in patients with chronic hepatitis B based on the detection of interferon ge
12/20/18 - A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Trial to Investigate the Proof of Concept of NPC-06 in Patients With Neuropathic Pain Associated With Cancer
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03773055, which has the following summary description: "The purpose of this trial is to investigate the efficiency of pain relief and the safety of NPC-06 for the neuropathic pain associated with cancer, in addition to explor
12/20/18 - A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03768375, which has the following summary description: "The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with FORFIRINOX in
12/20/18 - A Phase 1, Randomized, Open-label, Single-dose, 3-way Cross-over Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately (LOGAN)
By a News Reporter-Staff News Editor at Hepatitis Weekly Staff editors report on the newly launched clinical trial, NCT03772223, which has the following summary description: "This is a Phase 1 study to compare the pharmacokinetics of budesonide and albuterol delivered by PT027 compared with PT007 and PT008 administered separately." As a matter of
12/20/18 - A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention With Adjuvant Nivolumab in Non-Small Cell Lung Cancer Participants With ctDNA-detected Minimal Residual Disease After Surgical Resection
By a News Reporter-Staff News Editor at Cancer Vaccine Week Staff editors report on the newly launched clinical trial, NCT03770299, which has the following summary description: "The purpose of this study is to determine if nivolumab added to the standard of care therapy given after surgery is more effective than SOC alone in prolonging disease fr
12/20/18 - A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03773302, which has the following summary description: "Infigratinib is an oral medication which selectively binds to fibroblast grown factor receptor -2 and is being developed to treat participants with FGFR-2 mutated...
12/20/18 - A Phase I Safety and Tolerability Study of PP-001 Eye Drops in Healthy Adult Volunteers
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03769454, which has the following summary description: "In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits
12/20/18 - A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs)
By a News Reporter-Staff News Editor at Cancer Vaccine Week Staff editors report on the newly launched clinical trial, NCT03767582, which has the following summary description: "The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist with GVAX is safe in patients with locally advanced pancreatic ca
12/20/18 - A Phase II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
By a News Reporter-Staff News Editor at Hepatitis Weekly Staff editors report on the newly launched clinical trial, NCT03774082, which has the following summary description: "This open-label, single-arm, Phase II multi-center study will enroll approximately 42 subjects and investigate the activity, pharmacokinetics and safety of ruxolitinib added
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415